Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma. - Wikidata - awgldk - TriplyDB

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

http://www.wikidata.org/entity/Q37126978

about

Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma.Polymeric Nanoparticle-Mediated Gene Delivery for Lung Cancer Treatment.Cancer trials in sub-Saharan Africa: Aligning research and care.Should Response-Adapted Therapy Now Be the Standard of Care for Advanced Hodgkin's Lymphoma?Evolution of lymphoma staging and response evaluation: current limitations and future directions.Treatment outcomes for Hodgkin lymphoma: First report from the Brazilian Prospective Registry.Evaluating tumor response with FDG PET: updates on PERCIST, comparison with EORTC criteria and clues to future developments.Bleomycin pulmonary toxicity does not adversely affect the outcome of patients with Hodgkin lymphoma.FDG PET for therapy monitoring in Hodgkin and non-Hodgkin lymphomas.Comparison of the efficiency of ABVD versus BEACOPP for Hodgkin lymphoma treatment: a meta-analysis.ESMO consensus conference on malignant lymphoma: general perspectives and recommendations for prognostic tools in mature B-cell lymphomas and chronic lymphocytic leukaemia.Secondary malignant neoplasms, progression-free survival and overall survival in patients treated for Hodgkin lymphoma: A systematic review and meta-analysis of randomized clinical trials.Hodgkin lymphoma: a negative interim-PET cannot circumvent the need for end-of-treatment-PET evaluation.New agents in relapsed/refractory Hodgkin's lymphoma.The role of FDG-PET in Hodgkin lymphoma Frontline Therapy for Classical Hodgkin Lymphoma by Stage and Prognostic Factors.FDG-PET as a biomarker for early response in diffuse large B-cell lymphoma as well as in Hodgkin lymphoma? Ready for implementation in clinical practice?Modifying therapy in patients with advanced Hodgkin's lymphoma by integrating early metabolic response by interim PET-CT.Second cancer risk following Hodgkin lymphoma.Oncologists’ Perspectives on Consolidation Radiation Treatment after Chemotherapy for Lymphomas: A Survey Study by the Lymphoma Working Committee of the Turkish Oncology Group (TOG)Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma.Hodgkin lymphoma: A review and update on recent progress.18F-FDG PET/CT in Lymphoma: Has Imaging-Directed Personalized Medicine Become a Reality?Unproven value of end-of-treatment FDG-PET in Hodgkin lymphoma.The management of hodgkin lymphomas in pregnancies.PET-guided clinical trials in Hodgkin lymphoma: to agree or not to agree, that is the reviewer's question.Interim FDG-PET has no value in selecting patients who require treatment modification in both early- and advanced-stage Hodgkin lymphoma: response to Adams and Kwee.Lower socioeconomic status is independently associated with shorter survival in Hodgkin Lymphoma patients-An analysis from the Brazilian Hodgkin Lymphoma Registry.Hodgkin lymphoma: is there really a need for interim and end-of-treatment FDG-PET evaluations? - Response to Adams & Kwee.Predictive medicine: towards a multi-parametric imaging for a personal risk stratification.Assessment of alteration in liver 18F-FDG uptake due to steatosis in lymphoma patients and its impact on the Deauville score.Anti-PD-1 Antibodies as a Therapeutic Strategy in Classical Hodgkin Lymphoma.The predictive role of interim PET after the first chemotherapy cycle and sequential evaluation of response to ABVD in Hodgkin's lymphoma patients-the Polish Lymphoma Research Group (PLRG) Observational Study.Defining the optimal method for measuring baseline metabolic tumour volume in diffuse large B cell lymphoma.Treatment of Richter's Syndrome.Prognostic Utility of Total (68)Ga-DOTATATE-Avid Tumor Volume in Patients with Neuroendocrine Tumors.Serious concerns on the inability of FDG-PET in excluding residual viable lymphoma.Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma.Transplant strategies in relapsed/refractory Hodgkin lymphoma.Early warning signs: FDG-PET to diagnose bleomycin toxicity.

P2860

Q33442092-B4A64C51-7517-4F4E-8A18-805F8C0152B7 Q33824400-2CA00807-5BC4-4FD9-8701-E0269B642560 Q33887891-C2080526-891A-4439-8FA8-664B2B7FEA68 Q37694536-2F4962B7-8760-4701-8B59-0591706B1758 Q38671671-84B7C2F4-B5C3-48F2-B2CC-E92605E04C9B Q38712597-A10BBC35-5989-4E0B-A9B0-9ADD1E271ECB Q38737416-38B91DCB-F530-4FA1-BCBA-0B0B4D00842B Q38786377-133CE069-DD66-4E2C-A95A-8626DF433ECE Q38836081-C8FB2516-3DE4-456F-8C58-7892979FCCDE Q38929198-B548F98C-5D34-4B4F-9A23-2DFE388F7A6E Q39324849-DF9005BE-E4B1-41EA-9DE1-C987BDEA517B Q40040274-A124E463-F22E-41C9-95EB-B96519C5AA99 Q40616101-629722E7-9EC1-487B-BA14-C7B2681DF7E1 Q41500227-21DD3917-9F27-4BF0-9D21-07FD870EF2A3 Q41691698-B1518FE0-9AE2-4518-B786-417A3537B5EC Q42287385-92030E5E-550E-4739-8640-2724025DE3B4 Q42362028-FAAEB365-D5D6-40E4-A07C-65892866AC21 Q42370328-531D6101-1A2F-49CD-81F1-7A5194C2642B Q46123312-987E7DDE-F5D9-418B-97A9-0470B66AD6F5 Q47207408-D7F137C0-79DA-41F2-93FF-63403E848602 Q47563175-1A8C2993-8C1A-457A-9609-3054F24A7EEC Q47807176-7666C27E-C13D-46FE-BE34-B1C37257A027 Q47808320-92571A0D-9735-4E4B-828B-7C257CB9F568 Q48127652-9DDC7EE7-5416-473C-B788-6CC3C903B5B3 Q48162570-C47874CD-F26D-46D0-B518-B6532B3E7CE8 Q48194466-484A63DB-01DA-4E70-9C1A-0F4E026CBDA0 Q48194832-C4F4B1C8-1B42-49E4-9FD1-BD9BFAAD3EBA Q48202358-35CA9D13-F103-48E5-999C-06D56FB19148 Q48330706-57BE401A-DC32-43EE-8D8D-E58C4460C83B Q48332308-18FF4E91-B68C-4A0B-ABAF-4AFE2FFB01C7 Q48346684-85D06BD4-F23C-477C-A101-1FD97820FFE8 Q48689919-9ADD9BB1-BACD-433C-971D-A22C936BCE70 Q49821096-E4E82C81-1C37-4D61-810B-2AC6B248E5DE Q49827199-2484439A-FA3C-4E2E-90F9-FFF869A26B8D Q49843910-A9F8183F-9811-464B-B2DC-29FF1337894F Q49860792-CFAFFC00-68CD-4494-B68F-E40B1D1DCCC4 Q50058136-00B1DE92-9B76-499A-8B07-56CE527D2781 Q52569157-14512A8A-EFFD-4CAE-A694-6A64F22582E7 Q52676516-83A96A18-9DE0-41FE-B34B-B3DCEBCC3691 Q52952246-95AA89F0-9331-42DB-BBE7-556EC3D1DF87

P2860

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

http://www.wikidata.org/entity/Q37126978

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on June 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@en

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@nl

type

label

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@en

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@nl

prefLabel

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@en

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma.

@nl

P1433

Q37126978-79696AD4-64FA-4231-AF53-7AA5B8A0ECD5

P1476

Q37126978-F07DB0E7-83E2-4B9B-91D7-FADDE6C702E6

P2093

Q37126978-17413D56-C631-40AC-94CB-95DF4BA1C811

Q37126978-1F3DAE53-0449-4000-896F-4FC32DC2495F

Q37126978-3808EAEC-C77E-4DFC-9F57-4733AE243886

Q37126978-456486E4-5562-4194-A4E8-110965231990

Q37126978-6A2C37AF-2F26-4CA6-BF1E-B4FE7D462793

Q37126978-77B4FFDF-1979-470F-A9D1-909EBD718419

Q37126978-80CA7C37-6E6F-4D96-AF2C-0A99EFD02C61

Q37126978-88470BDE-F292-4A78-B4DC-198A68E95B64

Q37126978-9FDE522A-B0E9-449F-8DFD-91786262C6E9

Q37126978-A21E551D-9390-4D77-AB1A-74F25461C367

P2860

Q37126978-09E7BE67-2A94-4B05-A70B-B749267CACB4

Q37126978-0E7F7B0A-24D4-4E46-A4F9-67EC4EC27A04

Q37126978-1AC0B213-2523-41CD-A55A-EEA4B067AEEC

Q37126978-1BA7AF42-19F7-459B-9FB0-5D6D23BD7D5B

Q37126978-27A651A1-94A3-4CFF-91D9-C71CF5CBB365

Q37126978-3B824CCA-BF96-4965-895F-A3B35A370BF6

Q37126978-50AE54B2-3EBD-42D2-875D-2385D82779D0

Q37126978-50C38412-0D7A-4DF0-9B70-870C4625195C

Q37126978-58E430DA-0604-48C5-B374-5F25EF60A80C

Q37126978-5E248C8A-3830-4220-9F62-BEA7430DBD99

P304

Q37126978-7590C0BC-6640-472E-8B84-A781CE6DBF5A

P31

Q37126978-9B9AC9E6-967F-4118-8725-DE769F957743

P356

Q37126978-42F6874B-FB93-4D7F-9272-4BAA371F461D

P407

Q37126978-CE6E9B77-6791-4209-954F-612F55080275

P433

Q37126978-F306ADDF-F26A-4DC0-8DD0-0AC5A703860E

P478

Q37126978-DE1D6207-5547-4554-8CDC-A4C491E8364A

P50

Q37126978-16EDCA4E-A570-4AB3-B088-15D415CBA6AB

Q37126978-171EBECC-CC8B-4F68-8C5F-0479C77DA9DF

Q37126978-5CE306DA-0CAF-4C5C-BEAF-DE01EB3D269A

Q37126978-7EB1D5AB-5EEC-444A-9C81-435B2C09E4CC

Q37126978-9B7EB164-1A0F-4B50-A7A5-34A583FD0FE8

Q37126978-AA86CE1B-92DF-4803-BE32-B2B105B46925

Q37126978-AF1C467E-68C3-41EE-8741-1795E66EBBE1

P577

Q37126978-85390593-86C4-46F2-ACCD-FA01F15025D0

P698

Q37126978-BB9E17D1-6CA1-46EB-94A8-80536352160B

P932

Q37126978-65175659-CFA0-4779-AC6F-DDF65C7A48C4

P356

P1433

The New England Journal of Medicine

P1476

Adapted Treatment Guided by Interim PET-CT Scan in Advanced Hodgkin's Lymphoma

@en

P2093

Alexander Fosså

http://www.w3.org/2001/XMLSchema#string

Amy Kirkwood

http://www.w3.org/2001/XMLSchema#string

Angelo Carella

http://www.w3.org/2001/XMLSchema#string

Antonella Franceschetto

http://www.w3.org/2001/XMLSchema#string

Francesco d'Amore

http://www.w3.org/2001/XMLSchema#string

Gamal Sidra

http://www.w3.org/2001/XMLSchema#string

Gunilla Enblad

http://www.w3.org/2001/XMLSchema#string

Leanne Berkahn

http://www.w3.org/2001/XMLSchema#string

Lindsey Stevens

http://www.w3.org/2001/XMLSchema#string

Michael O'Doherty

http://www.w3.org/2001/XMLSchema#string

P2860

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Combination chemotherapy of Hodgkin's disease with adriamycin, bleomycin, vinblastine, and imidazole carboxamide versus MOPP

Bleomycin pulmonary toxicity has a negative impact on the outcome of patients with Hodgkin's lymphoma

ABVD for Hodgkin's lymphoma: full-dose chemotherapy without dose reductions or growth factors.

Establishment of a UK-wide network to facilitate the acquisition of quality assured FDG-PET data for clinical trials in lymphoma.

Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

ABVD versus BEACOPP for Hodgkin's lymphoma when high-dose salvage is planned.

Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.

Randomized comparison of the stanford V regimen and ABVD in the treatment of advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244.

Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial.

P304

2419-2429

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1510093

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

374

http://www.w3.org/2001/XMLSchema#string

P50

Peter W Johnson

Sally Barrington

Stefano Luminari

Massimo Federico

P577

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27332902

http://www.w3.org/2001/XMLSchema#string

P932

4961236

http://www.w3.org/2001/XMLSchema#string